Bisphosphonates for the preservation of periprosthetic bone mineral density after total joint arthroplasty: a meta-analysis of 25 randomized controlled trials
- 20 Downloads
The present meta-analysis aimed to evaluate the long-term efficacy of bisphosphonates (BPs) on preservation of periprosthetic bone mineral density (BMD) after joint arthroplasty. It confirmed the protective effect of BPs in a long-term follow-up, and found the influence factors on this effect.
Periprosthetic bone loss is believed to cause aseptic loosening and failed prosthetic fixation in joint arthroplasty. This meta-analysis which included high-quality randomized controlled trials aimed to analyze the effect of bisphosphonates on maintaining periprosthetic bone mineral density after total joint arthroplasty.
Twenty-five RCTs were included and the total number of participants was 1163 by computerized searches of bibliographic databases. The weighted mean differences with 95% confidence interval were calculated to evaluate the efficacy of BPs on total periprosthetic BMD and the BMD of different Gruen zones. Subgroup analyses identified the potentially influencing factors such as surgical site, cement fixation, and generation of BPs. A descriptive review was conducted for BP-related adverse effects.
The BPs group presented significantly higher total periprosthetic BMD in the BPs group than that in the control group at 3, 6, 12 months, 2–4 years, and 5–10 years after arthroplasty (P < 0.05). The BPs group presented significantly higher periprosthetic BMD in femoral Gruen Zone 1 and 7 than that in the control group at 3, 6, 12 months, 2–4 years, and 5–10 years (P < 0.05). The heterogeneity was minimized by dividing THA and TKA into two subgroups. Subgroup analyses revealed that the effect of BPs on preservation of BMD was significantly greater in arthroplasty with cemented component than in that with uncemented component at 12 months and 5–10 years (P < 0.05), and the administration of the second and third generation BPs was significantly more effective than the first-generation BPs at 6 and 12 months (P < 0.05). None of the included studies described severe or fatal adverse effects related to BPs.
BPs have significantly long-term efficacy on the preservation of periprosthetic BMD after joint arthroplasty. To obtain a better efficacy, the cemented components and the second and third generation BPs are recommended.
KeywordsArthroplasty Bisphosphonates Bone mineral density Meta-analysis
Compliance with ethical standards
Conflicts of interest
- 4.Iwamoto N, Inaba Y, Kobayashi N, Ishida T, Yukizawa Y, Saito T (2011) A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. J Bone Joint Surg Am 93(13):1203–1209CrossRefPubMedGoogle Scholar
- 9.Gruen TA, McNeice GM, Amstutz HC (1979) “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res 141:17–27Google Scholar
- 11.Mingmin Shi (2017). Effect of bisphosphonates on periprosthetic bone loss after total hip/knee arthroplasty. PROSPERO International prospective register of systematic reviews web. http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018085326. Acce3Assed 28 Jan 2018
- 17.Wang YM, Li X, Wang JQ, Guo SY (2005) Study on the periprosthetic bone loss after cemented primary total hip replacement. Tianjin Med J 33:492–494Google Scholar
- 22.Huang JF, Liu JB (2007) Alendronate prevents early femoral periprosthetic bone loss following total hip arthroplasty. J Jiangsu Univ (Medicine Edition) 17:542–544Google Scholar
- 31.Zeng JC, Zeng YR, Fan YG, Yin CZ, Li J, Li FL, Chen K (2014) The preliminary clinical study of Aclasta in preventing bone loss at the early stage after total hip arthroplasty. Chin J Osteoporos 20(07):795–799Google Scholar
- 34.Muren O, Akbarian E, Salemyr M, Bodén H, Eisler T, Stark A, Sköldenberg O (2015) No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial. Acta Orthop 86(5):569–574CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Huang TW, Wang CJ, Shih HN, Chang Y, Huang KC, Peng KT, Lee MS (2017) Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial. BMC Musculoskelet Disord 18(1):209CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009; 34:1929–1941Google Scholar
- 40.Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490CrossRefPubMedGoogle Scholar